Search clinical trials for: mild to moderate plaque psoriasis

Total 474786 results

AbbVie

Completed

Study of Subcutaneous (Injected Under the Skin) Risankizumab to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Plaque Psoriasis With Palmoplantar Involvement (IMMprint)

Psoriasis

United States, Canada, Puerto Rico, Spain
Samsung Bioepis Co., Ltd.
Organon and Co

Completed

Pharmacokinetics, Efficacy, Safety, and Immunogenicity of SB5 Versus Humira in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Plaque Psoriasis

Czechia, Lithuania, Poland, Bulgaria
Novartis Pharmaceuticals

Completed

Comparison of Secukinumab 300 mg Combined With a Lifestyle Intervention to Secukinumab Alone for the Treatment of Moderate to Severe Psoriasis Patients With Concomitant Metabolic Syndrome (METABOLYX)

Psoriasis | Metabolic Syndrome

Germany
Innovent Biologics (Suzhou) Co. Ltd.

Active, not recruiting

A Study to Evaluate IBI112 in the Treatment of Psoriasis With Moderate to Severe Plaque Psoriasis

Psoriasis

China
Shenzhen Kangzhe Pharmaceutical Co., Ltd.

Completed

A Phase Ⅲ Study to Evaluate Tildrakizumab in the Treatment of Chinese Subjects With Moderate to Severe Plaquetype Psoriasis

Plaque Psoriasis

China
Novartis Pharmaceuticals

Completed

Characteristics of Patients Treated With Secukinumab for Moderate to Severe Plaque Psoriasis

Plaque Psoriasis

Thailand
Novartis Pharmaceuticals

Completed

A Study of Moderate-to-severe Plaque Psoriasis Patients Response to Secukinumab Treatment in Real-world Setting

Moderate-to-severe Plaque Psoriasis

Indonesia
Eli Lilly and Company

Terminated

A Long-term Study to Evaluate Safety and Maintenance of Treatment Effect of LY3074828 in Participants With Moderate-to-Severe Plaque Psoriasis (OASIS-3)

Psoriasis

United States, Spain, Puerto Rico, Canada, France, Korea, Republic of, Germany, Australia, Italy, Israel, Poland, Japan, Argentina, Hungary, Taiwan, United Kingdom, Mexico, Czechia, Russian Federation
Almirall, S.A.

Completed

Efficacy and Safety of Tildrakizumab 100 Milligrams (mg) in Participants With Moderate-Severe Chronic Plaque Psoriasis and Its Impact on Their Quality of Life (TRIBUTE) (TRIBUTE)

Plaque Psoriasis

Spain, Italy
Akeso
Akeso Tiancheng, Inc

Completed

Clinical Study of AK101 in Subjects With Moderate to Severe Plaque Psoriasis

Plaque Psoriasis

China
Bioeq GmbH

Completed

A Double-blind Study to Compare the Efficacy, Safety, and Immunogenicity of the Proposed Biosimilar Ustekinumab FYB202 to Stelara® in Patients With Moderate-to-Severe Plaque Psoriasis (VESPUCCI)

Plaque Psoriasis

Poland, Estonia, Ukraine, Georgia
Sanofi

Completed

A Study to Investigate Safety, Tolerability and Clinical Response With SAR441566 Compared With Placebo in Participants With Mild to Moderate Psoriasis

Psoriasis

Germany
AbbVie

Enrolling by invitation

Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977 (OptIMMize-2)

Psoriasis

United States, Canada, Germany, Japan, Poland, Spain, United Kingdom
Alvotech Swiss AG

Completed

Efficacy, Safety, and Immunogenicity of AVT04 With Moderate-to-Severe Chronic Plaque Psoriasis

Psoriasis

Georgia, Estonia, Poland, Ukraine
UCB Biopharma SRL

Completed

A Study to Assess How Well Certolizumab Pegol Works in Patients With Moderate to Severe Plaque Psoriasis as Part of Routine Clinical Practice (CIMREAL)

Plaque Psoriasis

Belgium, Canada, Czechia, France, Germany, Greece, Italy, Spain, United Kingdom
University Hospitals Cleveland Medical Center

Completed

Monocyte Biomarkers in Moderate to Severe Plaque Psoriasis Subjects Treated With Apremilast

Plaque Psoriasis

United States
Actelion

Completed

ACT-128800 in Patients With Moderate to Severe Chronic Plaque Psoriasis

Psoriasis

Austria, Belgium, Bulgaria, Czechia, Denmark, France, Hungary, Italy, Lithuania, Romania, Russian Federation, Slovakia, Spain, Sweden, Switzerland, Ukraine, United Kingdom
Bristol-Myers Squibb

Completed

An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo and a Currently Available Treatment in Participants With Moderate-to-Severe Plaque Psoriasis (POETYK-PSO-2)

Psoriasis

United States, Spain, Hungary, Australia, Germany, Canada, Czechia, Poland, Puerto Rico, Finland, France, Israel, Italy, New Zealand, Sweden, United Kingdom
Samsung Bioepis Co., Ltd.

Completed

A Study to Compare SB17 (Proposed Ustekinumab Biosimilar) to Stelara® in Subject With Moderate to Severe Plaque Psoriasis

Psoriasis | Moderate to Severe Plaque Psoriasis

Czechia, Estonia, Hungary, Korea, Republic of, Latvia, Lithuania, Poland, Ukraine
General Hospital of Shenyang Military Region

Completed

Antiplatelet Therapy in Acute Mild-Moderate Ischemic Stroke (ATAMIS)

Ischemic Stroke

China
Sunshine Guojian Pharmaceutical (Shanghai) Co.,...

Active, not recruiting

A Phase 2 Study of Recombinant Anti-IL-17A Humanized Monoclonal Antibody in Chinese Participants With Moderate-to-Severe Plaque Psoriasis

Psoriasis

China
AbbVie

Completed

A Study Comparing the Safety and Efficacy of Risankizumab to Methotrexate in Subjects With Moderate to Severe Plaque Psoriasis

Psoriasis

Brazil
James G. Krueger, MD, PhD
Novartis

Completed

Safety and Efficacy of Secukinumab in Mild Psoriasis

Psoriasis

United States
Evelo Biosciences, Inc.

Completed

Study in Healthy Participants and Participants With Moderate Atopic Dermatitis & Optionally, Moderate Psoriasis, and/or Mild Asthma

Psoriasis | Asthma | Atopic Dermatitis

United Kingdom
Galderma R&D

Completed

Clobetasol Propionate Spray Versus Vehicle Spray for the Management of Moderate to Severe Plaque Psoriasis of the Scalp

Scalp Psoriasis

United States
Akeso

Completed

A Study of AK111 in Subjects With Moderate-to-severe Plaque Psoriasis

Psoriasis

China
Galderma R&D

Completed

Evaluate Safety/Efficacy of Two Treatment Regimens for Vectical™ Ointment & Clobex® Spray for Moderate Plaque Psoriasis

Plaque Psoriasis

United States, Canada
University of Michigan

Completed

The Effect of Riboflavin on Moderate to Severe Plaque Type Psoriasis

Psoriasis

United States
Huabo Biopharm Co., Ltd.

Completed

A Study of HB0017 in Patients With Moderate to Severe Plaque Psoriasis

Plaque Psoriasis

China
Novartis Pharmaceuticals

Completed

Evaluation of the Effectiveness of Secukinumab in Patients With Moderate to Severe Plaque Psoriasis

Plaque Psoriasis

United States
Can-Fite BioPharma

Completed

CF101 Therapy in Patients With Moderate-to-severe Plaque Psoriasis

Plaque Psoriasis

Israel, Serbia, Romania, Croatia, Bosnia and Herzegovina, Bulgaria, Canada, Moldova, Republic of, Poland
Biocad

Completed

An International Multicenter, Randomized, Double-blind, Placebo-Controlled Clinical Study of Efficacy and Safety of Two Dosing Regimens of BCD-085 (JSC BIOCAD, Russia) in Patients With Moderate to Severe Plaque Psoriasis (BCD-085-7)

Moderate to Severe Plaque Psoriasis

Russian Federation
Almirall, S.A.

Completed

Efficacy and Safety of Tildrakizumab in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Who Are Non-Responders to Dimethyl Fumarate Therapy (TRANSITION)

Plaque Psoriasis

United Kingdom, Germany
Shanghai Henlius Biotech

Completed

Study of Efficacy and Safety of HLX03 in Subjects With Moderate to Severe Plaque Psoriasis

Plaque Psoriasis

China
Alvotech Swiss AG

Completed

Pharmacokinetic, Efficacy, Safety, and Immunogenicity of AVT02 With Moderate to Severe Chronic Plaque Psoriasis

Plaque Psoriasis

Poland, Georgia, Iceland, Russian Federation, Ukraine
Dr. Reddy's Laboratories Limited
XenoPort, Inc.

Completed

A Study to Assess the Efficacy and Safety of XP23829 in Subjects With Moderate-to-Severe Chronic Plaque-Type Psoriasis

Psoriasis

United States
Saakshi Khattri

Completed

A Study to Evaluate the Efficacy and Safety of Secukinumab in Adult Patients With Skin Types IV-VI With Moderate to Severe Plaque Psoriasis

Psoriasis

United States
Idera Pharmaceuticals, Inc.

Completed

A 12-week Dose-Ranging Trial in Patients With Moderate to Severe Plaque Psoriasis (8400-201)

Plaque Psoriasis

Netherlands
Sun Pharmaceutical Industries Limited

Completed

A Study to Evaluate the Efficacy and Safety of Subcutaneous MK-3222, Followed by an Optional Long-Term Safety Extension Study, in Participants With Moderate-to-Severe Chronic Plaque Psoriasis (MK-3222-010) (reSURFACE 1)

Plaque Psoriasis
Kadmon Corporation, LLC

Completed

A Phase 2, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Belumosudil in Subjects With Moderate/Severe Chronic Plaque Psoriasis

Chronic Plaque Psoriasis

United States
Taro Pharmaceuticals USA

Completed

A Study Comparing Halobetasol Propionate and Tazarotene Topical Lotion 0.01%/0.045% to Duobrii® Lotion (Halobetasol Propionate and Tazarotene Lotion), 0.01%/0.045% (Reference Listed Drug) in the Treatment of Moderate to Severe Plaque Psoriasis.

Plaque Psoriasis

United States
Amgen

Completed

Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis. (ESTEEM 2)

Plaque Psoriasis

Spain, United States, Canada, Germany, Denmark, France, Italy, Switzerland, Austria
Amgen

Completed

Phase 3b Safety and Efficacy Study of Apremilast to Treat Moderate to Severe Plaque-plaque Psoriasis

Psoriasis | Psoriatic Arthritis

United States, Canada, United Kingdom, Australia, Hungary, Belgium, Netherlands, Germany, Czechia, Estonia, Latvia
Amgen

Completed

Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis (ESTEEM 1)

Plaque Psoriasis
Sun Pharmaceutical Industries Limited

Completed

A Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous Tildrakizumab (SCH 900222/MK-3222) in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Followed by a Long-term Extension Study (MK-3222-011) (reSURFACE 2)

Plaque Psoriasis
Sun Pharmaceutical Industries Limited

Withdrawn

A Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous MK-3222 in Participants With Moderate-to-Severe Chronic Plaque Psoriasis (MK-3222-012)

Plaque-type Psoriasis
MacroGenics
Eli Lilly and Company

Terminated

Safety Study of the Monoclonal Antibody Teplizumab (MGA031) in Subjects With Moderate or More Severe Psoriasis

Psoriasis

United States
Evelo Biosciences, Inc.

Completed

A Study of EDP1815 in Healthy Participants and Participants With Mild to Moderate Psoriasis and Atopic Dermatitis

Psoriasis | Atopic Dermatitis

United Kingdom
UCB Biopharma S.P.R.L.

Completed

A Study to Test the Efficacy and Safety of Certolizumab Pegol in Japanese Subjects With Moderate to Severe Chronic Psoriasis

Moderate to Severe Psoriasis | Generalized Pustular Psoriasis and Erythrodermic Psoriasis

Japan
Kiniksa Pharmaceuticals, Ltd.

Completed

A Study to Assess the Efficacy, Safety, and Tolerability of KPL-716 in Reducing Pruritus in Chronic Pruritic Diseases

Plaque Psoriasis | Chronic Idiopathic Urticaria | Lichen Planus | Lichen Simplex Chronicus | Chronic Idiopathic Pruritus

United States

3

Subscribe